Veronica Elizabeth Klepeis, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology, Clinical | 2 | 2021 | 375 | 0.540 |
Why?
|
| Leukemia, B-Cell | 1 | 2013 | 84 | 0.420 |
Why?
|
| Abdomen | 1 | 2013 | 1128 | 0.280 |
Why?
|
| Adenocarcinoma | 5 | 2016 | 6332 | 0.270 |
Why?
|
| Bone Marrow | 2 | 2014 | 2909 | 0.270 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2004 | 150 | 0.220 |
Why?
|
| Databases, Factual | 1 | 2016 | 7954 | 0.180 |
Why?
|
| Gap Junctions | 1 | 2001 | 230 | 0.170 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2021 | 110 | 0.170 |
Why?
|
| Epithelium, Corneal | 2 | 2007 | 252 | 0.170 |
Why?
|
| Epidermal Growth Factor | 2 | 2007 | 701 | 0.170 |
Why?
|
| Lung Neoplasms | 5 | 2016 | 13333 | 0.170 |
Why?
|
| Brain Abscess | 1 | 2020 | 120 | 0.160 |
Why?
|
| Mucormycosis | 1 | 2020 | 103 | 0.160 |
Why?
|
| Cornea | 3 | 2004 | 1332 | 0.150 |
Why?
|
| Calcium Signaling | 2 | 2001 | 733 | 0.150 |
Why?
|
| Cell Communication | 1 | 2004 | 1657 | 0.140 |
Why?
|
| Epithelial Cells | 4 | 2007 | 3666 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2021 | 703 | 0.130 |
Why?
|
| Facial Paralysis | 1 | 2020 | 345 | 0.130 |
Why?
|
| Orbital Pseudotumor | 1 | 2015 | 42 | 0.130 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 530 | 0.120 |
Why?
|
| Dacryocystitis | 1 | 2015 | 68 | 0.120 |
Why?
|
| Gelatinases | 2 | 2009 | 88 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 17 | 0.120 |
Why?
|
| Database Management Systems | 1 | 2016 | 257 | 0.120 |
Why?
|
| Cell Movement | 3 | 2007 | 5202 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 809 | 0.110 |
Why?
|
| Checklist | 1 | 2021 | 828 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 2509 | 0.110 |
Why?
|
| Endopeptidases | 1 | 1997 | 773 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2020 | 817 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2009 | 459 | 0.100 |
Why?
|
| Hematologic Tests | 1 | 2013 | 239 | 0.100 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2012 | 33 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2013 | 527 | 0.100 |
Why?
|
| Japan | 1 | 2016 | 1372 | 0.100 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 320 | 0.090 |
Why?
|
| Gene Rearrangement | 2 | 2015 | 1125 | 0.090 |
Why?
|
| Fatal Outcome | 2 | 2013 | 1833 | 0.090 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2009 | 42 | 0.090 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 534 | 0.080 |
Why?
|
| Enzyme Precursors | 1 | 2009 | 174 | 0.080 |
Why?
|
| Arthralgia | 1 | 2013 | 463 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2012 | 4063 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 8997 | 0.070 |
Why?
|
| Rabbits | 2 | 2004 | 4779 | 0.070 |
Why?
|
| Autopsy | 1 | 2009 | 1006 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 12972 | 0.060 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2004 | 13 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11070 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 1624 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 4740 | 0.060 |
Why?
|
| Kidney | 1 | 2020 | 7049 | 0.060 |
Why?
|
| Nucleotides | 1 | 2007 | 454 | 0.060 |
Why?
|
| Wound Healing | 3 | 2007 | 2802 | 0.060 |
Why?
|
| Recurrence | 2 | 2015 | 8470 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2009 | 6901 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4550 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4812 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 2248 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3638 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2013 | 2568 | 0.050 |
Why?
|
| Adenosine Triphosphate | 2 | 2007 | 1989 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1704 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 201 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2001 | 255 | 0.050 |
Why?
|
| Biopsy | 3 | 2021 | 6768 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2009 | 632 | 0.040 |
Why?
|
| Dysarthria | 1 | 2020 | 58 | 0.040 |
Why?
|
| Calcium | 2 | 2004 | 5726 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 591 | 0.040 |
Why?
|
| Solubility | 1 | 2001 | 1091 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2001 | 563 | 0.040 |
Why?
|
| Lacrimal Apparatus | 1 | 2001 | 223 | 0.040 |
Why?
|
| Heroin Dependence | 1 | 2020 | 172 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2001 | 618 | 0.040 |
Why?
|
| Peritoneal Dialysis | 1 | 2020 | 159 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 3613 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 336 | 0.040 |
Why?
|
| Pain | 1 | 2013 | 5077 | 0.040 |
Why?
|
| Cathepsin H | 1 | 1997 | 10 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 58946 | 0.040 |
Why?
|
| Cathepsin L | 1 | 1997 | 68 | 0.040 |
Why?
|
| Cathepsin B | 1 | 1997 | 80 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 6478 | 0.030 |
Why?
|
| Collagenases | 1 | 1997 | 222 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15262 | 0.030 |
Why?
|
| Cathepsins | 1 | 1997 | 241 | 0.030 |
Why?
|
| Humans | 17 | 2021 | 761326 | 0.030 |
Why?
|
| Prognosis | 5 | 2015 | 29588 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1997 | 393 | 0.030 |
Why?
|
| Sclerosis | 1 | 2015 | 210 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2013 | 11098 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 1959 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1997 | 551 | 0.030 |
Why?
|
| Aged | 7 | 2016 | 169179 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2001 | 2207 | 0.030 |
Why?
|
| Brain | 1 | 2020 | 27103 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 649 | 0.030 |
Why?
|
| Female | 8 | 2016 | 392485 | 0.030 |
Why?
|
| Middle Aged | 7 | 2016 | 220774 | 0.030 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2012 | 84 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 22158 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2012 | 82 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2002 | 4139 | 0.020 |
Why?
|
| Automation, Laboratory | 1 | 2012 | 103 | 0.020 |
Why?
|
| Male | 8 | 2020 | 360621 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1870 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 495 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2021 | 2221 | 0.020 |
Why?
|
| Cell Count | 1 | 2014 | 1835 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 650 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2016 | 80575 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2001 | 18962 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 2395 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1771 | 0.020 |
Why?
|
| ras Proteins | 1 | 2013 | 1053 | 0.020 |
Why?
|
| Receptors, Purinergic | 1 | 2007 | 66 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5970 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 1647 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1348 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2007 | 23427 | 0.020 |
Why?
|
| Adult | 6 | 2020 | 221122 | 0.020 |
Why?
|
| Triazines | 1 | 2007 | 311 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Child | 1 | 2013 | 80156 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3588 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 11900 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2909 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6473 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7389 | 0.010 |
Why?
|
| Phosphorylation | 2 | 2007 | 8312 | 0.010 |
Why?
|
| Thromboembolism | 1 | 2009 | 996 | 0.010 |
Why?
|
| Animals | 3 | 2004 | 168388 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6815 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 3611 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 1246 | 0.010 |
Why?
|
| ROC Curve | 1 | 2009 | 3572 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2012 | 2007 | 0.010 |
Why?
|
| Genomic Library | 1 | 2001 | 189 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 1545 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4509 | 0.010 |
Why?
|
| Pyridines | 1 | 2012 | 2870 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2001 | 211 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4244 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 4383 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2002 | 794 | 0.010 |
Why?
|
| Salivary Glands | 1 | 2001 | 229 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2001 | 430 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1650 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 5794 | 0.010 |
Why?
|
| Cause of Death | 1 | 2009 | 3685 | 0.010 |
Why?
|
| Mutation | 2 | 2014 | 30044 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12059 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12710 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2002 | 628 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 1900 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2001 | 803 | 0.010 |
Why?
|
| Pneumonia | 1 | 2009 | 2140 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 1992 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 3428 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13251 | 0.010 |
Why?
|
| Age Factors | 1 | 2014 | 18401 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 59196 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 828 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20555 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2002 | 12787 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2002 | 1330 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 1967 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3710 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 5670 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 5665 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 4175 | 0.010 |
Why?
|
| Exons | 1 | 2001 | 2392 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 1669 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 9275 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 16603 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 4466 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11735 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15599 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 17872 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12449 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10764 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13446 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13635 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17640 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2014 | 64645 | 0.000 |
Why?
|
| United States | 1 | 2015 | 72317 | 0.000 |
Why?
|
| Rats | 1 | 2001 | 23729 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2001 | 7852 | 0.000 |
Why?
|
| Risk Factors | 1 | 2009 | 74152 | 0.000 |
Why?
|